ClinicalTrials.gg

Carcinoma, Hepatocellular clinical trials

The registry lists 3,650 studies for Carcinoma, Hepatocellular across more than 10 countries. 1,062 are recruiting or about to start. 3,068 of them are mainly about Carcinoma, Hepatocellular (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Fibrolamellar hepatocellular carcinoma too: 3,663 studies, 1,065 open.

ClinicalTrials.gov finds 4,061 studies for Carcinoma, Hepatocellular. How that becomes 3,646 here

This page counts the studies the registry files under Carcinoma, Hepatocellular, and those it files under no condition that list Carcinoma, Hepatocellularthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 4,061Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −13Filed under a narrower condition, counted on its own pageFibrolamellar hepatocellular carcinoma 13
  3. −35List Carcinoma, Hepatocellular as a condition, but the registry did not file them under itMost often written as “Advanced Hepatocellular Carcinoma” (12), “Unresectable Hepatocellular Carcinoma” (5), and “Childhood Hepatocellular Carcinoma” (2). The registry filed them under other conditions only, most often Liver Neoplasms (17) and Carcinoma (5).
  4. −367Match it another way266 name it in the title, 3 in a keyword, and 98 by a synonym or other text the search reads.
  5. 3,646The count on this page266 of them list Carcinoma, Hepatocellular in their own words; the registry filed them under no condition.

Get an email when these change. Save the Carcinoma, Hepatocellular studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
1,241
Recruiting
737
Status unknown
683
Not yet recruiting
298
Terminated
296
Active, not recruiting
211

Phase

Phase 2
1,224
Phase 1
677
Phase 3
341
Phase 4
110
Early Phase 1
59

Where

China
1,309
United States
926
Korea, Republic of
297
France
284
Taiwan
273
Italy
206

What is being tested here

Drugs under test in Carcinoma, Hepatocellular studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 169 open · Tyrosine kinase inhibitors (TKIs) 96 open · Angiogenesis inhibitors 23 open · Antimetabolites 10 open · Alkylating agents 4 open

Coming up

332studies finish main data collection within a year22 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger. 31 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 31 (4%) take healthy volunteers.

Recruiting studies that take each age, of 737
AgeWomenMen
1028 (4%)28 (4%)
18683 (93%)683 (93%)
30726 (99%)726 (99%)
40726 (99%)726 (99%)
50727 (99%)727 (99%)
65723 (98%)723 (98%)
75681 (92%)681 (92%)
85428 (58%)428 (58%)

Across all 3,650 studies, recruiting or not: 29% stop at 75 or younger and 3% at 65; 6% take children; <1% are for women only and <1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Hepatocellular studies take

Of 428 phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 43 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 149 mo32–77 · 248 studies47 mo29–65 · 103 studies51 mo33–80 · 145 studies
Phase 1/253 mo38–76 · 136 studies47 mo35–74 · 72 studies—
Phase 243 mo30–71 · 428 studies38 mo23–50 · 80 studies47 mo33–78 · 348 studies
Phase 356 mo43–83 · 138 studies53 mo41–63 · 52 studies70 mo49–109 · 86 studies
Phase 468 mo24–118 · 38 studies——
Interventional, no phase47 mo23–75 · 384 studies—48 mo24–76 · 360 studies
Observational51 mo32–108 · 352 studies41 mo24–58 · 49 studies54 mo35–114 · 303 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Newly registered16

Show 11 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,650. Browse all 3,650 → or search them.